ATC Group: H05BX04 Etelcalcetide

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of H05BX04 in the ATC hierarchy

Level Code Title
1 H Systemic hormonal preparations, excl. Sex hormones and insulins
2 H05 Calcium homeostasis
3 H05B Anti-parathyroid agents
4 H05BX Other anti-parathyroid agents
5 H05BX04

Active ingredients in H05BX04

Active Ingredient Description
Etelcalcetide

Etelcalcetide is a synthetic peptide calcimimetic agent which reduces PTH secretion through binding and activation of the calcium-sensing receptor. Etelcalcetide is indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on haemodialysis therapy.

Related product monographs

Title Information Source Document Type  
PARSABIV Solution for injection European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Austria (AT)

Cyprus (CY)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Israel (IL)

Japan (JP)

Lithuania (LT)

Netherlands (NL)

Poland (PL)

Singapore (SG)

Spain (ES)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.